SavedAdd your journal

Journals / İstanbul Kanuni Sultan Süleyman Tıp Dergisi / 2015 / Cilt: 7 - Sayı: 1

Management of pregnancy affected by Kell alloimmunization: Case report

Kell alloimmunizasyonundan etkilenmiş gebeliğin yönetimi: Olgu Sunumu

Gökhan YILDIRIM
Melih BESTEL
Halil ASLAN
Ali EKİZ
Deniz AÇAR KANBER
Ahmet GÜL
Pages
44–46
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This patient had received 2 intrauterine transfusions which ended with successful live -births at 35th gestational week.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hemolytic disease of the fetus and newborn (HDFN), is acondition in which newborn s or fetus erythrocytes aredestroyed by maternally derived antibodies.
📊
Key Findings & Data:The incidence ofKell alloimmunization during pregnancy is between 0.1%-0.3%.
💡
Conclusion & Impact:This patient had received 2 intrauterine transfusions which ended with successful live -births at 35th gestational week.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hemolytic disease of the fetus and newborn (HDFN), is acondition in which newborn s or fetus erythrocytes aredestroyed by maternally derived antibodies. The most common type is the Rh (D) alloimmunization. The incidence ofKell alloimmunization during pregnancy is between 0.1%-0.3%. The mostly encountered minor blood type antibodiesare produced against Kell type. In this case report, a patient with a history of 3 pregnancy losses because of hydropsfetalis is being presented. This patient had received 2 intrauterine transfusions which ended with successful live -births at 35th gestational week.

Özet

Fetus ve yenidoğanın Hemolitik Hastalığı (FYHH), fetusunveya yenidoğanın eritrositlerinin maternal antikorlar aracılığı ile yıkılmasından kaynaklanır. En sık neden Rh (D)alloimmunizasyonudur. Kell alloimmunizasyonunun gebekadınlardaki insidansı %0,1-0,3 arasındadır. En sık görülen minör kan grubu antikorları Kelle karşı oluşmaktadır.Burada Kell alloimmunizasyonuna bağlı 3 kez hidropsfetalis ile gebelik kaybı olan hastada iki kez intrauterintransfüzyon sonrası 35. gebelik haftasında başarılı birdoğum sunulmaktadır.

🔖

Cite This Article

YILDIRIM, G., BESTEL, M., ASLAN, H., EKİZ, A., KANBER, D. A., GÜL, A. (2022). Management of pregnancy affected by Kell alloimmunization: Case report. İstanbul Kanuni Sultan Süleyman Tıp Dergisi, Cilt: 7 - Sayı: 1, 44–46. https://ajindex.com/articles/551136

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Koelewijn JM, Vrijkotte TG, van der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008;48:941.
  2. Geifman-Holtzman O, Wojtowycz M, Kosmas E, Artal R. Female alloimmunization with antibodies known to cause hemolytic disease. Obstet Gynecol 1997;89(2):272-5. http://dx.doi.org/10.1016/S0029-7844(96)00434-6 3. moise KJ. Fetal anemia due to to non-Rhesus-D red- cell alloimmunization. Semin Fetal Neonatal Med 2008;13(4):207-14.
  3. Mandelbrot l, Daffos F, Forestier F, MacAleese J, Descombey D. Assessment of fetal blood volume for computer-assisted management of in utero transfusion. Fetal Ther 1988;3(1-2):60-6.
  4. Vaughan JI, Warwick R, letsky E, Nicolini U, Rodeck CH et al. Erythropoietic supression in fetal anemia because of Kell alloimmunization. Am J Obstet Gnecol 1994;171:247.
  5. Schumacher B. moise KJ Jr. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet Gynecol 1996;88(1):137. http://dx.doi.org/10.1016/0029-7844(96)00113-5 7. moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012;120(5):1132-9.